A meta-analysis of outcomes and complications of magnetic resonance–guided focused ultrasound in the treatment of essential tremor

Nasser Mohammed, MD, MCh, Devi Patra, MD, MCh, and Anil Nanda, MD, MPH

Department of Neurosurgery, Louisiana State University Health Sciences Center, Shreveport, Louisiana

OBJECTIVE Magnetic resonance–guided focused ultrasound (MRgFUS) is a novel technique that uses high-intensity focused ultrasound to achieve target ablation. Like a lens focusing the sun’s rays, the ultrasound waves are focused to generate heat. This therapy combines the noninvasiveness of Gamma Knife thalamotomy and the real-time ablation of deep brain stimulation with acceptable complication rates. The aim of this study was to analyze the overall outcomes and complications of MRgFUS in the treatment of essential tremor (ET).

METHODS A meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was made by searching PubMed, Cochrane library database, Web of Science, and Cumulative Index to Nursing and Allied Health Literature (CINAHL). Patients with the diagnosis of ET who were treated with MRgFUS were included in the study. The change in the Clinical Rating Scale for Tremor (CRST) score after treatment was analyzed. The improvement in disability was assessed with the Quality of Life in Essential Tremor Questionnaire (QUEST) score. The pooled data were analyzed by the DerSimonian-Laird random-effects model. Tests for bias and heterogeneity were performed.

RESULTS Nine studies with 160 patients who had ET were included in the meta-analysis. The ventral intermediate nucleus was the target in 8 of the studies. The cerebellothalamic tract was targeted in 1 study. There was 1 randomized controlled trial, 6 studies were retrospective, and 2 were prospective. The mean number of sonications given in various studies ranged from 11 ± 3.2 to 22.5 ± 7.5 (mean ± SD). The maximum delivered energy ranged from 10,320 ± 4537 to 14,497 ± 6695 Joules. The mean of peak temperature reached ranged from 53°C ± 2.3°C to 62.0°C ± 2.5°C. On meta-analysis with the random-effects model, the pooled percentage improvements in the CRST Total, CRST Part A, CRST Part C, and QUEST scores were 62.2%, 62.4%, 69.1%, and 46.5%, respectively. Dizziness was the most common in-procedure complication, occurring in 43.4%, followed by nausea and vomiting in 26.8% (pooled percentage). At 3 months, ataxia was the most common complication, occurring in 43.4%, followed by ataxia and vomiting in 26.8% (pooled percentage). At 12 months posttreatment, the ataxia had significantly recovered and paresthesias became the most common persisting complication, at 15.3%.

CONCLUSIONS The MRgFUS therapy for ET significantly improves the CRST scores and improves the quality of life in patients with ET, with an acceptable complication rate. Therapy with MRgFUS is a promising frontier in functional neurosurgery.

https://thejns.org/doi/abs/10.3171/2017.11.FOCUS17628

KEY WORDS MR-guided focused ultrasound; essential tremor; ventral intermediate nucleus; thalamotomy

HIGH-INTENSITY focused ultrasound is a novel and emerging technique that uses ultrasound waves as carriers of energy. It was used as early as the 1950s for the treatment of Parkinson disease. After the advent of levodopa therapy, its application was forgotten.12 Focused ultrasound came back to modern relevance with its use in prostate cancer in 1994.26 The ultrasound waves

traverse intervening tissues and generate heat at the point of focus. The use of the phased-array transducer technique allows for ultrasound beam steering and focusing without attenuation. Ultrasound waves interact with biological tissue, producing a variety of effects, like acoustic cavitation, shear stress, and thermal effect. The ultrasound waves cause vibrations of molecules, which in turn gen-

ABBREVIATIONS CRST = Clinical Rating Scale for Tremor; CTT = cerebellothalamic tract; DBS = deep brain stimulation; ET = essential tremor; GKT = Gamma Knife thalamotomy; MRgFUS = MR-guided focused ultrasound; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; QUEST = Quality of Life in Essential Tremor Questionnaire; RCT = randomized controlled trial; Vim = ventral intermediate nucleus.


INCLUDE WHEN CITING DOI: 10.3171/2017.11.FOCUS17628.
erates frictional heat. Protein denaturation or coagulative necrosis occurs in the cells at a temperature of 56°C for 1 second.\textsuperscript{18} Because sound produces an alternating rarefaction, this generates acoustic cavitation. The skull presents a high acoustic impedance to the ultrasound as it absorbs and reflects the waves. Another problem with the bone is that it may cause aberration of the waves. There is heat generation in the skull due to this, and external cooling has to be done in between the sonications. The present study is aimed at understanding the outcomes and complications of this fascinating new technology in the treatment of essential tremor (ET).

Essential tremor is the most common adult movement disorder, occurring at a crude prevalence of 0.08–220 per thousand persons.\textsuperscript{25} Essential tremor can be viewed more as a syndrome of different clinical features than a single entity.\textsuperscript{10} The presence of ET can cause significant functional and psychological disability, and hence the term “benign” has largely been abandoned in its nomenclature.\textsuperscript{14} The incidence is higher in the white than in the African American population.\textsuperscript{24} Increasing age has been consistently associated with the incidence and prevalence of ET.\textsuperscript{7} The tremor in ET is both kinetic and postural, and may involve other parts of the body, like the head, voice, jaw, tongue, or legs.\textsuperscript{7} The primary therapy for ET is medical treatment. Medical therapy alone is able to reduce tremor in 50%–60% of patients.\textsuperscript{5,6} Pharmacological therapy is the first line and mainstay of ET treatment. However, it has been estimated that 25%–55% of patients do not show a clinically satisfactory response to medical therapy alone.\textsuperscript{11,39} Abnormal cerebellothalamic outflow has been hypothesized as the factor that leads to ET.\textsuperscript{16,23} The ventral intermediate nucleus (Vim) of the thalamus is a relay nucleus in the thalamus through which the cerebellothalamic tract (CTT) pathway proceeds, and is the target site for ablation.\textsuperscript{36} The high density of fibers and its distance from the sensory nucleus make the CTT a target for ablation.\textsuperscript{32}

**Methods**

The aim of the study was to analyze the outcomes of MR-guided focused ultrasound (MRgFUS) therapy in the treatment of ET. The outcome parameters that were analyzed were the Clinical Rating Scale for Tremor (CRST) scores and the scale’s subsections. The quality of life and disability improvement was assessed using the Quality of Life in Essential Tremor Questionnaire (QUEST) score. A detailed protocol about the literature search, inclusion and exclusion criteria, selection of cases, and statistical methodology was developed. The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed. Two investigators (N.M. and D.P.) performed the literature search independently. To minimize selection bias, 2 reviewers assessed the articles independently. In case of doubt, a mutual consensus was reached after discussion with the senior author.

**Literature Search Strategy**

A computerized Web search of the titles and abstracts from January 1950 to August 2017 in PubMed, Cochrane library database, Web of Science, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) was performed. A combination of key word searches was made to build a search strategy. The non-English articles were also searched. An independent Web search was made with the key words to include any unpublished literature (Fig. 1A). Some of the key words that were used to build the search directory were “focused ultrasound,” “essential tremor,” “ventrointermediate nucleus,” “deep brain stimulation,” “thalamotomy,” and “MR-guided.”

![PRISMA Protocol](https://example.com/prisma.png)

**FIG. 1.** The PRISMA flowchart and funnel plot. A: The PRISMA flowchart. B: A funnel plot of the studies evaluating CRST Total scores. The plot shows an unequal distribution of studies and the presence of bias. The fail-safe test was performed. The number of missing studies that would bring the p value to > α was found to be 1.
Tremor Scoring System

The CRST is a scoring system used to evaluate the severity of the ET. The CRST has 3 parts.33 Part A evaluates the tremor, Part B evaluates task performance, and Part C evaluates the disability due to the tremor. The 3 parts contribute to a total of 160 points; higher scores reflect a more severe tremor. Part A has a score range from 0 to 32 summarizing 8 items, and is the primary clinical end point of interest. The baseline and posttreatment CRST scores were noted. The QUEST scoring was also used to evaluate the quality of life improvement following the treatment. The QUEST is scored from 0% to 100%; higher scores reflect a greater perceived disability.

Bias Assessment

Two investigators independently reviewed all the articles to eliminate the selection bias. A meta-analysis of proportions was performed. The present study involves mainly observational studies and 1 randomized controlled trial (RCT). Funnel plots were charted. The Q statistic and I² were calculated to assess heterogeneity. The I² value was high in most analyses, indicating increased heterogeneity.

Inclusion and Exclusion Criteria

The diagnosis of ET was based on the consensus statement of the Movement Disorder Society. The inclusion criteria consist of the presence of bilateral postural tremor with or without kinetic component tremor, involving hands and forearms, that is visible and persistent—lasting for more than 5 years. The diagnosed cases of ET that were treated with MRgFUS were included in the study. All the cases that were treated with MRgFUS were refractory to medical therapy. Medication-refractory tremor was defined as persistent disabling tremor despite at least 2 trials of a full-dose therapeutic medication, 1 of which had to include propranolol or primidone. The cases of ET that were associated with Parkinson disease and those treated with deep brain stimulation (DBS) or stereotactic ablative excision were excluded. For the purpose of statistical analysis, only studies that assessed the tremor outcome by using the CRST were included. The diagnosis of ET was based on the Movement Disorder Society’s consensus statement. The cases in which the patient had suffered a head injury prior to 3 months of onset of tremor, cases with a psychogenic origin, those with abnormal neurological signs, drug-induced or drug-withdrawal–related cases, or those with a known cause of physiological tremor were excluded from the study.5

Tremor Scoring System

The CRST is a scoring system used to evaluate the severity of the ET. The CRST has 3 parts.33 Part A evaluates the tremor, Part B evaluates task performance, and Part C evaluates the disability due to the tremor. The 3 parts contribute to a total of 160 points; higher scores reflect a more severe tremor. Part A has a score range from 0 to 32 summarizing 8 items, and is the primary clinical end point of interest. The baseline and posttreatment CRST scores were noted. The QUEST scoring was also used to evaluate the quality of life improvement following the treatment. The QUEST is scored from 0% to 100%; higher scores reflect a greater perceived disability.

Statistical Analysis

Statistical analysis was done using Comprehensive Meta Analysis software (version 3.3.070). Due to the inherent heterogeneity of observational studies, the random-effects model was used for the meta-analysis. The meta-analysis of proportions was performed, as was the test for heterogeneity. The I² value and Q statistic were evaluated. The DerSimonian-Laird model was used to calculate the pooled effect. Forest plots were charted for the tremor score subsections. Bias assessment was done using the funnel plots (Fig. 1B).

Results

Nine studies with 160 patients who matched the inclusion and exclusion criterion were considered for the present study (Table 1). The mean age was highest in the study by Schreglmann et al.,32 at 70.7 ± 8.5 years, and lowest in that of Kim et al.,19 at 64.7 years. The means of the duration of tremor in patients in various studies ranged from 12.1 years to 32 years. The Vim was the target in 8 studies, whereas the CTT was targeted in 1 study.32 There was 1 RCT, 6 studies were retrospective, and 2 were prospective. There were 2 studies from Elias et al.8,9 The first was a pilot study, including 15 patients.8 The second was an RCT that included 56 patients.8 The mean number of sonifications given in various studies ranged from 11 ± 3.232 to 22.5 ± 7.632 (mean ± SD). The maximum delivered energy ranged from 10,320 ± 4,537 Joules to 14,497 ± 6,695 Joules.8 The mean of peak temperature reached ranged from 53°C ± 2.3°C to 62.0°C ± 2.5°C.

The tremor was evaluated using the CRST.33 The base-
line scores and postprocedure improvement of the scores were recorded. The mean percentage change in the score was then calculated. The results were subjected to meta-analysis and the pooled percentage change in the scores was obtained. The complications were divided into 3 groups. Complications occurring during the procedure were analyzed separately as a group. The CRST Total and CRST Part A scores were subdivided into 2 groups. Those complications that occurred at 3 or 6 months were grouped together to evaluate the short-term outcomes, and those that occurred at 12 months were analyzed separately to evaluate the long-term outcomes, whereas the CRST Part C score that assessed the disability was studied at 6 or 12 months only. The CRST Part B score was included in the CRST Total score and was not calculated separately. The pooled percentage of complications at different time periods was then analyzed.

The CRST Total Score

The CRST Total score at baseline was compared with that of postprocedure scores. The CRST Total scores showed good improvement in all studies. The latest CRST score was used to compare the results. The study by Elias et al.9 showed the lowest improvement in the scores at 35%. The highest improvement in the tremor score was in the study by Chang et al., at 80.43%.4 The study by Kim et al.10 did not report the actual CRST Total scores, but reported the percentage of patients who had improvement in the ET. This study was not included in the statistical analysis for CRST Total scores. On meta-analysis with the random-effects model, the pooled improvement in the CRST Total scores was 62.2%. The improvement in score reflects the reduction in the severity and associated disability due to the tremor (Fig. 2A and Table 2).

The CRST Part A Score

The CRST Part A score evaluates the hand tremor severity and is the principal end point of interest in treatment of ET. Higher scores reflect more severe tremor. All studies showed good improvement in the hand tremor severity (Table 2). The percentage improvement in the score ranged from 35.07%15 to 88.42%.4 The pooled percentage improvement of the CRST Part A study after the meta-analysis is 62.4% (Fig. 2B).

The CRST Part C and QUEST Scores

The CRST Part C score takes into consideration the disability due to the ET. Higher scores reflect greater disability. The percentage improvement indicates the reduction in disability. The pooled analysis showed a 69.1% reduction in the CRST Part C scores due to the treatment. The QUEST score also evaluates the improvement in disability due to ET after the treatment. The pooled improvement in QUEST scores after the analysis was 46.5% (Fig. 2C and D).

In-Procedure Complications

In-procedure complications are those that occur during the sonication and that resolve following completion of the treatment. The common complications that occurred in the studies included headache, dizzy feeling, nausea and vomiting, sensation of warmth in the scalp or flushing, and paresthesias (Table 3). Dizziness was the most common in-procedure complication that occurred. The pooled percentage of in-procedure dizziness occurring in patients was found to be 43.4%. Nausea and vomiting is the next most frequent in-procedure complication, occurring at 26.8% (pooled estimate). The percentage of occurrence of in-procedure headache, sensation of warmth or
flushing, and paresthesias was found to be 24.3%, 19.8%, and 13.1%, respectively. The frame-related complications were also included in this group. Ten instances of pin site complications were noted. There were 4 cases of pin site burns, 9 cases of occipital numbness, and 6 cases of pin site hematoma. Chang et al. noted 3 cases of failure to reach the target temperature despite increasing the energy and number of sonications. One patient in the study by Lipsman et al. developed deep venous thrombosis secondary to the length of the procedure (Fig. 3A and B).

**Complications at 3 Months After Treatment**

Ataxia, which includes both objective gait instability and subjective feeling of unsteadiness, was the most com-

### TABLE 2. Baseline CRST Total, Part A, Part C, and QUEST scores, and percentage improvement at 3, 6, or 12 months

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>CRST Total Score at Baseline (mean ± SD)</th>
<th>CRST Total Score at 3 or 6 Mos (mean ± SD)</th>
<th>CRST Total Score at 12 Mos (mean ± SD)</th>
<th>CRST Total Score, % Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zaaoroo et al., 2018</td>
<td>40.7 ± 11.6</td>
<td>8.2 ± 5.0 (6 mos)</td>
<td>NS</td>
<td>79.85</td>
</tr>
<tr>
<td>Schreglmann et al., 2017</td>
<td>43.8 ± 9.8</td>
<td>19.8 ± 6.8 (6 mos)</td>
<td>NS</td>
<td>54.79</td>
</tr>
<tr>
<td>Elias et al., 2013</td>
<td>54.9 ± 14.4</td>
<td>NS</td>
<td>24.3 ± 14.8</td>
<td>56</td>
</tr>
<tr>
<td>Lipsman et al., 2013</td>
<td>70.75 ± 19.6</td>
<td>35.25 ± 10.9 (3 mos)</td>
<td>NS</td>
<td>50.17</td>
</tr>
<tr>
<td>Huss et al., 2015</td>
<td>54.9</td>
<td>NS</td>
<td>17.7</td>
<td>67.75</td>
</tr>
<tr>
<td>Kim et al., 2017</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>78.3% improved at 12 mos</td>
</tr>
<tr>
<td>Chang et al., 2015</td>
<td>46.72 ± 10.51</td>
<td>6.25 ± 7.16 (6 mos)</td>
<td>NS</td>
<td>80.43</td>
</tr>
<tr>
<td>Wintermark et al., 2014</td>
<td>19.8 ± 5*</td>
<td>4.6 ± 3 (3 mos)</td>
<td>NS</td>
<td>76.5</td>
</tr>
<tr>
<td>Elias et al., 2016</td>
<td>50.1 ± 14.0</td>
<td>29.6 ± 13 (3 mos)</td>
<td>32.4 ± 14.5</td>
<td>35</td>
</tr>
</tbody>
</table>

### TABLE 3. In-procedure complications

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Headache</th>
<th>Dizzy Feeling</th>
<th>Nausea &amp; Vomiting</th>
<th>Sensation of Heat, Warmth, or Flushing</th>
<th>Scalp Tingling</th>
<th>Paresthesias</th>
<th>Frame Related &amp; Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zaaoroo et al., 2018</td>
<td>0</td>
<td>14</td>
<td>5</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>Scalp numbness (5), subcutaneous hematoma (3)</td>
</tr>
<tr>
<td>Schreglmann et al., 2017</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Elias et al., 2013</td>
<td>9</td>
<td>5</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Lipsman et al., 2013</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Huss et al., 2015</td>
<td>9</td>
<td>11</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>MRI pin site burn (2)</td>
</tr>
<tr>
<td>Kim et al., 2017</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Chang et al., 2015</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Sonication failures (3)</td>
</tr>
<tr>
<td>Wintermark et al., 2014</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Pin site burn (2), occipital numbness (4)</td>
</tr>
<tr>
<td>Elias et al., 2016</td>
<td>2</td>
<td>12</td>
<td>13</td>
<td>17</td>
<td>0</td>
<td>4</td>
<td>Pin site edema (3), back pain (5), anxiety (3)</td>
</tr>
</tbody>
</table>
mon complaint at 3 months (Table 4). The pooled estimate of ataxia occurring at 3 months was 32.8%. In other words, one-third of the patients had some form of gait instability persisting at 3 months posttreatment. Paresthesias were the next most common complication persisting at 3 months. The meta-analysis showed that 25.1% of patients had this complication at 3 months. Other complications, like dysarthria, limb weakness, dysmetria, tinnitus, fatigue, and dysgeusia, occurred at the rate of 4.1%, 5.6%, 8.4%, 5.35%, 5.35%, and 4.4%, respectively (pooled percentage; Fig. 3C and D).

Complications at 12 Months After Treatment

At 12 months, paresthesias became the most common persisting complaint. Approximately 15.3% of the patients continued to have paresthesias at 12 months posttreatment. Paresthesias involved the lips and finger areas. Ataxia, which was the most common complaint at 3 months, had completely resolved in a majority of patients; it was present in 10.5% of the patients at 12 months. One patient had persisting facial paresis at 12 months. Thus, there was a significant reduction in the number of persisting complications at the end of 12 months after treatment with MRgFUS for ET (Fig. 3E and F).

Discussion

Two parameters were the focus of this study. The first was to analyze the improvement in the CRST score following the treatment, and the second was to categorize the complications temporally and estimate their overall inci-
dence. All the studies demonstrated a good improvement in the total tremor scores and the subsections of the CRST scores. Our analysis showed a significant improvement of CRST Total scores, CRST Part A scores, CRST Part C scores, and QUEST scores by 62.2%, 62.4%, 69.1%, and 46.5%, respectively. The study by Elias et al., which included 56 patients, was the only RCT. This study showed a significant 35% improvement in the CRST Total score at 12 months. Importantly, the improvements in tremor scores were maintained at 12 months. Gait disturbance and paresthesias occurred in 36% and 38% of the patients at 3 months and in 9% and 14% at the end of 12 months, respectively.

In the study by Chang et al., patients in 3 cases failed to achieve the target temperature despite increasing the intensity and number of sonications. The authors found a linear correlation between skull volume and the maximum temperature reached at the target site. Schreglmann et al. was the only study that targeted the CTT. No paresthesias were found in their patients with complications. This can be explained by the distance of the CTT from the ventro-posterior nucleus, which relays the sensory fibers. Another complication noted in the present study was pin site burn due to MRI-induced heating of the pins.

After its FDA approval in 1997, DBS has become the current standard surgical treatment for medication-refractory ET. It was Benabid and colleagues in 1987 who showed the beneficial effects of high-frequency stimulation of the Vim in the thalamus in reducing tremor. The Vim is the target of DBS in the treatment of ET. Several studies have shown that subthalamic regions below the Vim, like the radiation prelemniscal and caudal zona incerta, can also improve the symptoms of ET when selected as targets. Loss of tremor control can occur gradually over the years following DBS. This has been suggested to be due to tolerance, and the stimulation parameters can be adjusted. The total tremor score improvements in various studies range from 34% to 83%. Kenney et al. studied 319 patients treated with DBS, of which 112 patients had ET. The in-procedure adverse events included vasovagal response in 2.5%, severe cough in 0.9%, transient ischemic attack in 0.3%, arrhythmia in 0.3%, and confusion in 0.3% of the patients. Perioperative complications included headache in 15%, confusion in 5%, hallucinations in 2.8%, seizures in 1.2%, intracerebral hemorrhage in 0.6%, and intraventricular hemorrhage and large subdural hemorrhage in 0.3% of the patients. Persistent long-term complications were dysarthria in 4%, gait disturbance in 3.8%, cognitive dysfunction in 4%, and infection in 4.4%. To add to the list, hardware problems like lead fractures and migrations also occurred.

A revision rate of 7.8% was noted in this series. Other series have shown that hardware complications like lead fracture, infection, skin erosion, and cable connection failure occur in up to one-quarter of patients. Okun et al. found suboptimally placed electrodes in 46%, inadequate follow-up programming in 17%, and suboptimal DBS parameters in 37% of the cases. Voges et al. analyzed the complication rate after DBS in 1183 patients and found a 30-day mortality rate of 0.4% and permanent surgical morbidity at 1%. However, DBS is not an ablative procedure. Some of the complications can be reduced or eliminated.
by adjusting the stimulation parameters. This reversibility is not possible in ablative procedures like thalamotomy and MRgFUS. It should also be noted that although DBS is reversible and nonablative, it is still invasive—and complications like hemorrhage, seizures, suboptimal electrode placement, and infection can occur.

Gamma Knife thalamotomy (GKT) is a noninvasive procedure that lacks the real-time feedback of tremor reduction and electrophysiological confirmation. The radiation takes time (months to years) to show the clinical improvement. Radiotherapy takes time (months to years) to show the clinical response. The usual dose used is 130–140 Gy, delivered by a single 4-mm collimator. The GKT procedure is done usually when the patients are unable to receive DBS, such as those on anticoagulation in whom DBS is risky. Advanced age, medical comorbidities, and patient preferences are other factors that may influence the choice of GKT. Accuracy of targeting is not as good as the intraoperative electrophysiological monitoring done in DBS. The size of the lesion produced by GKT may vary due to unpredictable tissue response to radiation.

Kondziolka et al., in a study of 31 patients with ET who were treated with GKT, showed a 69% improvement in both action tremor and writing scores. There was a 12% failure rate. Jankovic et al. reported a 58% temporary complication rate following stereotactic thalamotomy and a 23% permanent complication rate. Complications like hemiparesis, altered mental status, thalamic hemorrhage, and homonymous hemianopia have been reported.

Radiation necrosis and collateral trajectory tissue damage are a concern. Because of these considerations, GKT is not recommended as a first line of treatment for ET.

Justification for our Analysis

The MRgFUS technique is relatively new. The outcomes and complications are reported in a small number of studies, and the number of patients in each study is small. This report has been an effort to bring together the studies that have used MRgFUS for the treatment of ET and to understand its overall impact and the associated complications. A meta-analysis generates a broader perspective by combining the results of all the studies, and summarizes the outcomes and complications. There is a paucity of class 1 studies in this fascinating new frontier. An important goal of this study was to summarize the various complications and their incidences temporally.

Limitations of the Study

There are a number of limitations of the present study. Most of the included studies were retrospective case series; only 1 RCT was included. Thus, the possibility of bias is high (Table 5). The follow-up period is small. Longer follow-up is required to assess the long-term tremor suppression and complications due to the treatment. The number of patients is small; larger trials with randomization are required. Randomized trials comparing DBS to MRgFUS are the need of the hour.

Conclusions

The MRgFUS therapy for ET significantly improves the CRST scores and improves the quality of life of patients with ET, with an acceptable rate of complications. The MRgFUS therapy is a promising frontier in functional neurosurgery.

Acknowledgments

We thank Julia M. Esparza, MLS, AHIP, an associate professor in the Department of Medical Library Science/Health Sciences Library, LSU Health, Shreveport, LA, for assisting in the search strategy. We also thank Ms. Gloria Caldito, an associate professor in the Department of Statistics and Research, LSU, for assistance with the statistical analysis.

References


### Table 5. Summary of critical appraisal of included studies using the Newcastle-Ottawa Scale for assessing the quality of observational studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Selection</th>
<th>Comparability</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zaaroor et al., 2018</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Schregmann et al., 2017</td>
<td>**</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Elias et al., 2013</td>
<td>**</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Lipsman et al., 2013</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huss et al., 2015</td>
<td>***</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>Kim et al., 2017</td>
<td>***</td>
<td>**</td>
<td>*</td>
</tr>
<tr>
<td>Chang et al., 2015</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wintermark et al., 2014</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elias et al., 2016</td>
<td>****</td>
<td>**</td>
<td>***</td>
</tr>
</tbody>
</table>

Each of the 3 categories has further subcategories of assessment for which an asterisk is given. Studies with the maximum number of asterisks have a higher quality than those with fewer asterisks. Empty cells indicate that no asterisks could be scored for that category.

Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Nanda, Mohammed. Acquisition of data: Nanda, Mohammed. Analysis and interpretation of data: Nanda, Mohammed. Drafting the article: Nanda, Mohammed. Critically revising the article: Nanda, Mohammed. Reviewed submitted version of manuscript: Nanda, Mohammed. Approved the final version of the manuscript on behalf of all authors: Nanda. Statistical analysis: Mohammed. Administrative/technical/material support: all authors. Study supervision: all authors.

Correspondence
Anil Nanda: Louisiana State University Health Sciences Center, Shreveport, LA. ananda@lsuhsc.edu